Compounds > 2-cyano-3-(1-phenylindol-3-yl)acrylate
Page last updated: 2024-08-02 00:32:13

2-cyano-3-(1-phenylindol-3-yl)acrylate

Description

2-cyano-3-(1-phenylindol-3-yl)acrylate: inhibits pyruvate transport into mitochondria [MeSH]

Cross-References

ID SourceID
PubMed CID6438504
CHEMBL ID4303684
SCHEMBL ID16620642
MeSH IDM0128325

Synonyms (36)

Synonym
uk-5099
uk 5099
56396-35-1
2-propenoic acid, 2-cyano-3-(1-phenyl-1h-indol-3-yl)-
uk5099
2-cpiya
(e)-2-cyano-3-(1-phenylindol-3-yl)prop-2-enoic acid
HY-15475
CS-1048 ,
alpha-cyano-beta-(1-phenylindol-3-yl)acrylate
2-cyano-3-(1-phenylindol-3-yl)acrylate
BCPP000027
2-cyano-3-(1-phenyl-1h-indol-3-yl)-2-propenoic acid
pf-1005023
S5317
2-cyano-3-(1-phenyl-1h-indol-3-yl)-acrylic acid
AKOS024458020
SCHEMBL16620642
2-cyano-3-(1-phenyl-1h-indol-3-yl)prop-2-enoic acid
AS-63568
i2r ,
uk-5099, >=98% (hplc)
(e)-2-cyano-3-(1-phenyl-1h-indol-3-yl)acrylic acid
2260696-90-8
2-cyano-3-(1-phenyl-1h-indol-3-yl)acrylic acid
A12644
CCG-267359
CHEMBL4303684
alpha-cyano-beta-(1-phenylindol-3-yl)-acrylate
gtpl11302
nsc784390
nsc-784390
uk5099; pf-1005023
EX-A1928
2-cyano-3-(1-phenyl-1h-indol-3-yl)acrylicacid
AC-36255

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1708853Inhibition of MPC in human MCF-10A cells assessed as increase in cellular lactate production incubated for 24 to 30 hrs2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
ISSN: 1520-4804		Development of Novel Mitochondrial Pyruvate Carrier Inhibitors to Treat Hair Loss.
AID1708852Inhibition of MPC in human MCF-10A cells assessed as increase in cellular lactate production at 10 uM incubated for 24 to 30 hrs2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
ISSN: 1520-4804		Development of Novel Mitochondrial Pyruvate Carrier Inhibitors to Treat Hair Loss.
AID1708855Inhibition of MPC in human MCF-10A cells assessed as reduction in oxygen consumption rate using pyruvate and malate and ADP2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
ISSN: 1520-4804		Development of Novel Mitochondrial Pyruvate Carrier Inhibitors to Treat Hair Loss.

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (10.00)18.7374
1990's5 (16.67)18.2507
2000's1 (3.33)29.6817
2010's13 (43.33)24.3611
2020's8 (26.67)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (96.67%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
alpha-cyanocinnamate
1
202120213.0low000001
alpha-cyano-4-hydroxycinnamic acid
1
monohydroxycinnamic acid;
nitrile;
phenols		MALDI matrix material202120213.0low000001
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
acetyl phosphate
1
acyl monophosphateEscherichia coli metabolite;
human metabolite;
mouse metabolite		201820186.0low000010
chlorine
1
halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite		1993199331.0low001000
lactic acid
7
2-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite		199820219.0medium001051
pyruvic acid
12
2-oxo monocarboxylic acidcofactor;
fundamental metabolite		1984202114.7high021162
alpha-cyano-4-hydroxycinnamate
2
1984198738.5low020000
verapamil
1
aromatic ether;
nitrile;
polyether;
tertiary amino compound		1997199727.0low001000
valproic acid
1
branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent		202120213.0low000001
glyburide
1
monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent		1997199727.0low001000
metformin
1
guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic		201720177.0low000010
minoxidil
1
dialkylarylamine;
tertiary amino compound		202120213.0low000001
troglitazone
1
chromanes;
thiazolidinone		anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent		202320231.0low000001
alanine
1
alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite		202120213.0low000001
glutamine
1
amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite		201520159.0low000010
adenosine diphosphate
1
adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		fundamental metabolite;
human metabolite		2014201410.0low000010
cycloserine
1
4-amino-1,2-oxazolidin-3-one;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic;
zwitterion		antiinfective agent;
antimetabolite;
antitubercular agent;
metabolite;
NMDA receptor agonist		202120213.0low000001
thiophenes
1
mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent201720177.0low000010
3,5-diiodosalicylic acid
1
1993199331.0low001000
finasteride
1
3-oxo steroid;
aza-steroid;
delta-lactam		androgen antagonist;
antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor		202120213.0low000001
tenidap
2
1997199727.0low002000
2-aminomethyl-4-t-butyl-6-iodophenol
1
1993199331.0low001000
glycogen
1
201520159.0low000010
acetyl coenzyme a
1
acyl-CoAacyl donor;
coenzyme;
effector;
fundamental metabolite		201720177.0low000010
ferulic acid
1
ferulic acidsanti-inflammatory agent;
antioxidant;
apoptosis inhibitor;
cardioprotective agent;
MALDI matrix material;
plant metabolite		201720177.0low000010
caffeic acid
1
caffeic acidgeroprotector;
mouse metabolite		201720177.0low000010
nadp
1
2014201410.0low000010
4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid
1
stilbenoid1993199331.0low001000
sirolimus
1
antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor		201720177.0low000010
4,4'-diisothiocyanostilbene-2,2'-disulfonic acid
1
1997199727.0low001000
azd3965
1
201720177.0low000010
nad
1
organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite		202120213.0low000001
cytochrome c-t
1
2013201311.0low000010
glucagon
1
peptide hormone1984198440.0low010000
hoe 33342
1
2005200519.0low000100
salicylates
1
monohydroxybenzoateplant metabolite1993199331.0low001000
piroxicam
1
benzothiazine;
monocarboxylic acid amide;
pyridines		analgesic;
antirheumatic drug;
cyclooxygenase 1 inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug		1997199727.0low001000
pyrimidinones
1
201720177.0low000010
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Adenocarcinoma0
1
201820186.0low000010
Adenocarcinoma, Basal Cell0
1
201820186.0low000010
Alopecia0
2
202120213.0low000002
Alopecia Cicatrisata0
2
202120213.0low000002
Cancer of Colon0
1
201820186.0low000010
Cancer of Kidney0
1
201720177.0low000010
Cancer of Liver0
1
201720177.0low000010
Cancer of Prostate0
1
201520159.0low000010
Cirrhosis0
1
202320231.0low000001
Colonic Neoplasms0
1
201820186.0low000010
Diabetes Mellitus, Adult-Onset0
1
202120213.0low000001
Diabetes Mellitus, Type 20
1
202120213.0low000001
Disease Models, Animal0
1
201720177.0low000010
Experimental Hepatoma0
1
201720177.0low000010
Fibrosis0
1
202320231.0low000001
Germinoblastoma0
1
201720177.0low000010
Hyperglycemia0
1
201520159.0low000010
Hyperglycemia, Postprandial0
1
201520159.0low000010
Kidney Neoplasms0
1
201720177.0low000010
Koch's Disease0
1
201720177.0low000010
Liver Neoplasms0
1
201720177.0low000010
Lymphoma0
1
201720177.0low000010
Mesothelioma0
1
201820186.0low000010
Neoplasms, Pleural0
1
201820186.0low000010
Obesity0
1
201520159.0low000010
Prostatic Neoplasms0
1
201520159.0low000010
Tuberculosis0
1
201720177.0low000010

Pharmacokinetics (1)

ArticleYear
Determination and pharmacokinetics study of UK-5099 in mouse plasma by LC-MS/MS.
BMC veterinary research, , Apr-20, Volume: 18, Issue:1		2022